Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Change in Inventory (2020 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Change in Inventory for 6 consecutive years, with $4.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Inventory rose 27.86% year-over-year to $4.0 million, compared with a TTM value of $19.3 million through Dec 2025, up 119.61%, and an annual FY2025 reading of $19.3 million, up 119.61% over the prior year.
  • Change in Inventory was $4.0 million for Q4 2025 at Xeris Biopharma Holdings, down from $4.1 million in the prior quarter.
  • Across five years, Change in Inventory topped out at $7.6 million in Q2 2025 and bottomed at $148000.0 in Q2 2022.
  • Average Change in Inventory over 5 years is $2.9 million, with a median of $2.3 million recorded in 2021.
  • The sharpest move saw Change in Inventory plummeted 95.49% in 2022, then surged 4922.3% in 2023.
  • Year by year, Change in Inventory stood at $2.3 million in 2021, then skyrocketed by 142.08% to $5.5 million in 2022, then plummeted by 74.55% to $1.4 million in 2023, then skyrocketed by 123.91% to $3.1 million in 2024, then rose by 27.86% to $4.0 million in 2025.
  • Business Quant data shows Change in Inventory for XERS at $4.0 million in Q4 2025, $4.1 million in Q3 2025, and $7.6 million in Q2 2025.